Beckman Coulter Life Sciences and Rarity Bioscience AB sign Partnership
March 5th, 2025, Indianapolis, US. Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, in partnership with Rarity Bioscience AB offers a...
RheaVita Announces Strategic Partnership With IMA Life
Ghent, Belgium, 18 November 2024, RheaVita Announces Strategic Partnership With IMA Life, Part of the IMA Group, to Drive Further Technological Development and Commercial Growth.
Novalis II portfolio company Trince awarded winner of Nature Spinoff Prize 2024
July 11th 2024, Ghent (BE). Novalis II portfolio company Trince is awarded the Spinoff Prize from the prestigious Nature Magazine
Anacura acquires OHMX.bio, a Novalis fund I portfolio company, and extends its service with multi-omics for drug discovery and diagnostics
July 4th, 2024. Ghent, Belgium Anacura acquires OHMX.bio, a Novalis fund I portfolio company, and extends its service with multi-omics for drug discovery and diagnostics
Rarity Bioscience announces the successful closure of a €6.5 million funding round
June, 18th 2024, Uppsala, Sweden. Rarity Bioscience, a pioneering molecular biotech company, is pleased to announce the successful closure of a €6.5 million funding round....
Alithea Genomics Closes CHF 2.8 Million in Seed Financing Extension Led by Novalis Biotech
Alithea Genomics, an emerging leader in the field of large-scale RNA sequencing and transcriptomics, announced today the closing of a CHF 2.8 million ($3.2 million)...
RheumaFinder Announces Investment to revolutionize care for patients with rheumatic disease
Ghent, Belgium, February 2024 – RheumaFinder is excited to announce an investment from Belgium's Novalis Biotech Acceleration Fund. This investment, executed as a seed-participation in...
Altavo concludes Series A for the development of its Artificial Voice
Altavo, a startup in AI-based voice rehabilitation founded in 2021, successfully closed its Series A financing round on February 1, 2024.
myNEO evolves into myNEO Therapeutics to reflect its new strategy to develop off-the-shelf cancer vaccine immunotherapeutics.
myNEO evolves into myNEO Therapeutics to reflect its new strategy to develop off-the-shelf cancer vaccine immunotherapeutics.
Novalis Biotech invests in Rarity Bioscience’s ultra sensitive genomics technology
Uppsala, Sweden, 06 Feb 2023 To further accelerate growth, Rarity Bioscience announces today a new strategic investment from Belgium based Novalis Biotech. The investment is...
C-mo Medical Solutions extends seed investment round to €4.8 million to transform cough monitoring
C-mo Medical Solutions has announced an extension to its seed investment round. The round now totals €4.8 million and with the addition of Novalis Biotech...
Enzyre closes Series A financing round of EUR 12M to advance pioneering diagnostic technology platform for hemophilia patients
Funds will be used to accelerate development of proprietary ambulant diagnostic platform and to expand platform beyond hemophilia A.
Carroucell Raises €1.5 Million to Introduce Breakthrough Microcarriers to Cell and Gene Therapy Market
Funding Consist of Series A Financing from Novalis Biotech and Crédit Agricole des Savoie, as well as support from Bpifrance
CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development
Novalis Fund I portfolio company myNEO and CureVac (Nasdaq: CVAC) closed a partnership to identify novel targets for mRNA-based cancer vaccine development.
Alithea Genomics Raises CHF 1 Million in Seed Financing Round Led by Novalis Biotech
Proceeds to Enable Commercialization and Scale-Up of Unique RNA Sequencing Technology
New start-up Trince raises EUR 4 million for innovative technology to produce personalized cancer therapies safer, cheaper, and faster
Trince, a spin-off of Ghent University (UGent), is developing innovative and efficient technology to insert genetic material into cells.
Novalis Biotech Acceleration Modality.AI – technology that ‘self-drives’ neurological and psychiatric assessments
Modality.AI, pioneering AI technology for assessing neurological and psychiatric conditions remotely and in clinical settings through speech and facial measurements, has received a $2.1 million...
Epigenetics company Epify progresses colorectal cancer program and files first patent application
Maastricht, The Netherlands, July 6, 2021 - Epify announces a patent filing in the colorectal cancer (CRC) program. The patent claims multiple epigenetic...
Novalis Biotech Closes €25 Million Biotech Acceleration Fund
Second Healthcare Fund Invests in Start-ups and Scale-ups Advancing Transformative Healthcare Technologies
RheaVita Closes EUR 2.5 million Series A Financing Co-Led by Novalis Biotech Acceleration and PMV
Ghent, Belgium, June 2, 2021 , RheaVita Closes EUR 2.5 million Series A Financing Co-Led by Novalis Biotech Acceleration and PMV
OncoDNA and myNEO Join Forces to Unlock the Power of Personalised Vaccines
OncoDNA, a company specializing in precision medicine, and myNEO, an AI-driven company revolutionizing target identification within immuno-oncology, are thrilled to announce today a new collaboration in...
Enzyre announces strategic partnership with Takeda to accelerate development of pioneering diagnostic technology platform for hemophilia patients
4 th March 2021, Nijmegen, Netherlands: Enzyre, which is developing breakthrough ambulant diagnostic technology...
Grapheal raises EUR1.9 million from Novalis Biotech, BPI France and private investors, as well as non-dilutive grants
Grapheal raises EUR1.9 million to advance development of embedded biosensing technology
Doc.ai acquired by Sharecare
28 January 2021, PALO ALTO, Calif. Doc.ai, one of the first investments of Novalis Biotech Incubation (Fund I) has been acquired by Sharecare.
Novalis Biotech Announces First Closing of its Second Healthcare Fund
23 November 2020, Ghent, Belgium, Novalis Biotech, an early stage venture capital investor in technologies to revolutionize healthcare, announced today the successful first closing of...
Novalis invests in Enzyre to support development of Enzypad, a breakthrough hand-held diagnostic and monitoring device
27 July 2020, Nijmegen, The Netherlands, Enzyre, a developer of breakthrough diagnostic technology to bring the lab to the patient...
myNEO develops universal Covid-19 vaccine with technology for cancer treatment
02 Jul 2020, Ghent, Belgium, myNEO announces that promising Covid-19 peptides have been identified which will undergo further preclinical testing. By making smart use of...
Novalis Biotech Incubation to invest in Cergentis
20 May 2020, Utrecht, The Netherlands, Novalis Biotech Incubation, a Belgian venture capital investment fund, is investing seed capital in Cergentis for an undisclosed amount.
myNEO and VUB-LMCT collaborate on Covid-19
11 May 2020, myNEO collaborates with VUB-LMCT to develop assays for immunogenicity validation of predicted SARS-CoV-2 epitopes
myNEO prepares for clinical trial with Persomed for treatment of Colorectal Cancer
27 April 2020, Persomed joint venture anounces development of a personalised colon cancer vaccine.
BioLizard in the press: Liesbeth Ceelen and Wim Van Criekinge highlight the importance of Bioinformatics
February 2020, Liesbeth Ceelen (Biolizard) and Novalis founder Wim Van Criekinge appear in the Belgian press, highlighting the importance of Bioinformatics.
Epify Strengthens Management Team by Appointing Leander Van Neste as Chief Scientific Officer
Maastricht, The Netherlands, November 7, 2019 -- Epify BV is a recently established biotechnology company that translates sound epigenetic biomarker discoveries into clinical practice to...
Official launch of OHMX.bio, partner for high-throughput OMICS solutions
Ghent, 14 October 2019. Novalis and Ghent University are proud to release OHMX.bio (www.ohmx.bio), the sixth instalment in Novalis’ portfolio of biotechnology and life sciences...
Novalis participates in financing round of FERTIGA for further expansion of the Corona Test
Ghent, Belgium, 09 Oct 2019. Fertiga, the Belgian female fertility company, announces the closure of its first financing round together with Novalis Biotech Incubation and...
Epify raises 500,000 Euro in seeding round
Maastricht, 26 September 2019. Epify is a recently established biotech company that translates sound epigenetic biomarker discoveries into clinical practice to help doctors improve the...
AI Meets Genome Sequencing and the Health Data Explosion to Transform Medicine
We’ve discussed the questions of “nature vs nurture”, personalized medicine and the privacy of genomics data with Dr. Wim Van Criekinge, Chief Life Science Officer...
Wobblebase genome importer from Novalis integrated in doc.ai medical data platform
In October 2018, Wobblebase’s genome importer has been integrated in the doc.ai platform. Biotech incubator Novalis is now the second largest external shareholder in doc.ai.
MyNeo has been officially launched today!
Ghent, 27th December 2018. MyNeo has started its life as an independent entity! MyNeo is a Belgian biotech company, based in Ghent, focused on identifying,...
Launch of BioLizard’s website, lizard.bio!
Today we announce the launch of lizard.bio, where we describe our experience in bioinformatics, biostatistics and machine learning, applied to the biotechnology field.
De Tijd interviews Novalis’s founders
De Tijd journalist Jan De Schamphelaere discusses the launch of Novalis with our founders, from their previous careers to the current state of the fund.
Novalis founds first three companies
We are proud to announce to the world the incorporation of BioLizard, OHMX.bio and MyNeo.
Novalis becomes a member of flanders.bio
Novalis makes its entry in the Flemish biotech scene, and invites resumés to fill various positions. We’re also interested in learning about your latest research,...